Recent Trends and the Future of Antimicrobial Agents provides a significantly expanded overview of the topic with updated research in a broader context on the development of alternative approaches against microbial infections. This part consists of ten chapters. The first five chapters describe naturally derived antimicrobial compounds such as plant-based antimicrobials (PBAs), enzymes-based and antibody-based antibacterial therapeutic and secondary metabolites from plant endophytes. The book proceeds to provide details about antimicrobials derived from marine microorganisms (bacteria, fungi, actinomycetes, and cyanobacteria) is included to inform readers about effective medications against MDR strains. Specific chapters describe the drug development against protozoans, with one chapter focusing on Plasmodium. Chapter contributors have postulated novel approaches for antimalarial therapeutics. The book also includes an explanation of host target identification and drug discovery with the purpose of informing the reader about the implications in viral biology and how they could be exploited for treating viral diseases. The contents cater to the information needs of professionals and learners in academia, industry and health services who aim to learn the most significant experimental and practical approaches towards finding alternatives to existing antimicrobial therapies.

The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease's progression along with extrahepatic manifestations and virus invasion strategies impacting the host's immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management. Topics covered in the chapters include 1) HCV-host interactions leading to asymptomatic acute infection, 2) the progression of acute HCV infection to chronic disease and subsequent extrahepatic comorbidities, 3) Innate and adaptive immune responses in HCV infections, 4) Consensus-based Approaches for Hepatitis C Screening and Diagnosis, 5) advances in hepatitis C therapy and global management of HCV, and 6) the outcomes of Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. This book is a valuable addition to undergraduate and postgraduate hepatology students and physicians, clinicians, hepatologists, and health care officials involved in HCV clinical diagnosis and therapeutics.

In this third year of the SARS-CoV-2 pandemic responsible for COVD-19 and related diseases worldwide, the scientific studies and reviews focused on this virus and its variants are still crucial. The third volume of the Coronaviruses series brings together some essential data regarding the origin, pathology and chemotherapeutic drugs to treat coronavirus infections. Contributions are written by experienced researchers with the goal of updating medical researchers and clinicians dealing with COVID-19 patients. It presents seven chapters covering a range of topics: (1) bat coronaviruses in the world, (2) hospital challenges during the COVID-19 pandemic, (3) the pro-inflammatory and thrombotic manifestations and the therapeutic options of Covid-19, (4) the common and rare dermatologic manifestations registered in COVID-19 patients, (5) the circulating biomarkers of cardiopulmonary disturbances in COVID-19, and (6) the aspects of pathology and pathogenesis of coronavirus infection

This compendium represents a set of guides to understanding the challenging scientific, epidemiological, clinical, social, and economic phenomenon that is represented by the COVID-19 pandemic. The book explains the mathematical modeling of COVID-19 infection, with emphasis on traditional epidemiological principles. It represents a rigorous, comprehensive and multidisciplinary approach to a complex phenomenon. The chapters take into account the knowledge arising from different disciplines (epidemiology, pathophysiology, immunology, medicine, biology, vaccine development, etc.). It also covers COVID-19 data analysis, giving the reader a perspective of statistics and data science, and includes a discussion about social and economic issues of the pandemic. Each chapter is devoted to a specific topic, and is contributed by experts in epidemiology. Because of its multidisciplinary nature, this book is intended as a reference on mathematical models and basic immunotherapy for COVID-19 for a broad community of readers, from scholars who have scientific training, to general readers who have an interest in the disease.

Coronavirus disease 2019 (COVID-19) has affected millions of people across the world. Clinicians and scientists across the globe need all the information of this pandemic on one platform. Today, it is also necessary to find out the association of COVID-19 with various medical comorbidities, and its effect on vulnerable populations that require special medical attention. This information will be helpful for the management of COVID-19. COVID-19: Effects in Comorbidities and Special Populations is a concise and visual reference for information about this viral disease and its relationship with different medical conditions. The book provides comprehensive knowledge covering COVID-19 comorbidities (for example, CVD, Diabetes, lung diseases, etc.), and the incidence in specific groups (for example, children and the elderly). Chapters outline the features and the management of the disease in specific conditions. Key Features: - 12 chapters covering several aspects of COVID-19 management, making this a perfect text book for virologist and medical students - Focused and structured description of different effects of COVID-19 in specific patient groups - Multiple tables and figures which summarizes and highlight important points - Multiple choice questions for learners - Detailed list of references, abbreviations and symbols This book is an essential reference for practicing and training virologists, pulmonologists, medical students and scientists working in research labs, pharmaceutical and biotechnology industries in connection with the control of COVID-19 infection.

This update on SARS-CoV-2 focuses on basic knowledge about the virus and COVID-19 treatment. Chapters present basic information about the disease and its treatment. The virology, epidemiology, etiology, and damage response framework of SARS-CoV-2 are also discussed in detail. The book also covers recent topics of interest to pharmacology scholars such as the immunopathogenesis of SARS-CoV2, nanotechnology, repurposed drug treatments, COVID-19 vaccines, and phytomedicine for COVID-19 therapeutics. Readers in pharmacology, virology and medicine will find the book a simple, yet informative update on SARS-CoV-2 and COVID-19 treatment.

An Epidemiological Update on COVID-19 brings recent findings about the pandemic to the forefront. The reference is a compilation of eleven chapters contributed by expert scholars in epidemiology and medicine that cover topics of interest to anyone interested in COVID-19 monitoring and response measures. The topics also indicate some clinical areas of interest to COVID-19 researchers that have received attention due to the pandemic. It covers basic knowledge about respiratory conditions associated with SARS-CoV-2 infection and COVID-19 epidemiology. These topics are complemented with chapters detailing the symptoms and biochemical mechanisms of novel coronavirus infections intended for readers with an advanced level of understanding of life sciences and medicine. Special topics such as the immune response to Sars-CoV-2, and, recombinant drugs for COVID-19, are also covered in this book. Each chapter is organized in a reader-friendly format and includes a list of references.

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. Volume 11 of this series brings together reviews covering immunotherapy of sepsis, new antimalarials, and the medicinal use of onions for respiratory diseases, among other topics. Topics included in this volume are: - Heme-oxygenase and autophagy connected as a cytoprotective mechanism: potential therapeutic target - Development of recombinant therapeutic proteins in animal cells: Challenges and solutions - Artemisinin Analogues as a Novel Class of Antimalarial Agents: Recent Developments, Current Scenario and Future Perspectives - The effects of Allium cepa and their derivatives on respiratory diseases and the possible mechanisms of these effects - Immunotherapy of Sepsis

Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are: - Monoclonal antibodies as therapeutic agents for inflammatory diseases - Pharmacotherapy of emerging antiviral agents - Antiviral activity of vitamin D and COVID-19: current understanding - Anti-infectives to combat leishmaniasis - Anthelmintic drug discovery: current situation and future perspectives - Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials - Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees